On Friday, May 11, 2018, President Trump vowed to fix “the injustice of high drug prices” by announcing the “Blueprint to Lower Drug Prices” (the Blueprint) to address the following challenges:
- Excessively high drug prices
- Seniors and government programs overpaying for drugs
- High out-of-pocket costs for consumers
- Lack of transparency in drug pricing
- Free-riding by foreign nations as to US investment in innovation
This piece provides analysis of the Blueprint and its proposed reforms.